TGFB2 and neoplasm: In the tumor microenvironment, high CD8+ T-cell infiltration correlates with better prognosis [49]; in ‘hot’ tumors, CTL-rich tumors respond better to immunotherapy [49,51] Our results suggest that TGFB2 mRNA blockade can improve the prognosis of patients with TMEs with low CD8+ T-cell infiltration, providing clinicians with an additional therapeutic modality.